Your browser doesn't support javascript.
loading
A TLR7 agonist activates bovine Th1 response and exerts antiviral activity against bovine leukemia virus.
Sajiki, Yamato; Konnai, Satoru; Okagawa, Tomohiro; Maekawa, Naoya; Nakamura, Hayato; Kato, Yukinari; Suzuki, Yasuhiko; Murata, Shiro; Ohashi, Kazuhiko.
Afiliación
  • Sajiki Y; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: y.sajiki@vetmed.hokudai.ac.jp.
  • Konnai S; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: konnai@vetmed.hokudai.ac.jp.
  • Okagawa T; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: okagawa@vetmed.hokudai.ac.jp.
  • Maekawa N; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: maekawa@vetmed.hokudai.ac.jp.
  • Nakamura H; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: btbw-h314@eis.hokudai.ac.jp.
  • Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan; New Industry Creation Hatchery Center, Tohoku University, Sendai, 980-8575, Japan. Electronic address: yukinarikato@med.tohoku.ac.jp.
  • Suzuki Y; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan; Division of Bioresources, Research Center for Zoonosis Control, Hokkaido University, Sapporo, 001-0019, Japan. Electronic address: suzuki@czc.hokudai.ac.jp.
  • Murata S; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: murata@vetmed.hokudai.ac.jp.
  • Ohashi K; Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan; Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. Electronic address: okazu@vetmed.hokudai.ac.jp.
Dev Comp Immunol ; 114: 103847, 2021 01.
Article en En | MEDLINE | ID: mdl-32888966
ABSTRACT
Bovine leukemia virus (BLV) infection is a bovine chronic infection caused by BLV, a member of the genus Deltaretrovirus. In this study, we examined the immunomodulatory effects of GS-9620, a toll-like receptor (TLR) 7 agonist, in cattle (Bos taurus) and its therapeutic potential for treating BLV infection. GS-9620 induced cytokine production in peripheral blood mononuclear cells (PBMCs) as well as CD80 expression in CD11c+ cells and increased CD69 and interferon (IFN)-γ expressions in T cells. Removing CD11c+ cells from PBMCs decreased CD69 expression in T cells in the presence of GS-9620. These results suggest that TLR7 agonism promotes T-cell activation via CD11c+ cells. Analyses using PBMCs from BLV-infected cattle revealed that TLR7 expression in CD11c+ cells was upregulated during late-stage BLV infection. Furthermore, GS-9620 increased IFN-γ and TNF-α production and inhibited syncytium formation in vitro, suggesting that GS-9620 may be used to treat BLV infection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Pteridinas / Leucosis Bovina Enzoótica / Virus de la Leucemia Bovina / Células TH1 / Receptor Toll-Like 7 Límite: Animals Idioma: En Revista: Dev Comp Immunol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Pteridinas / Leucosis Bovina Enzoótica / Virus de la Leucemia Bovina / Células TH1 / Receptor Toll-Like 7 Límite: Animals Idioma: En Revista: Dev Comp Immunol Año: 2021 Tipo del documento: Article
...